Gilead Jumps With Analysts Upbeat on HIV Drug IP Settlement (1)

(Updates share price move)

Gilead Sciences gains as much as 5.5% to hit the highest level since Jan. 25, after saying it has entered into agreements with generic manufacturers Lupin Ltd., Apotex Inc., Macleods Pharma Ltd., Hetero Labs Ltd. and Cipla Ltd. to resolve the litigation and patent challenges associated with Descovy, Vemlidy and Odefsey in the US District Court for the District of Delaware.

• Pacts grant the generic manufacturers a non-exclusive license in the US to the company’s patents on tenofovir alafenamide (TAF) relating to Descovy and Vemlidy beginning on Oct. 31, 2031, and to Odefsey beginning on Jan. ...